|
| General Information |
| Business: |
We are a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. Our lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
36 |
Founded: |
2010 |
|
| Contact Information |
| Address: |
343 Oyster Point Blvd., Suite 200, South San Francisco, CA 94080, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -17.0 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
CALA |
| Shares (millions): |
8.0 |
| Price Range: |
$10.00 - $10.00 |
| Est.$ Volume |
$ 80.0 mil |
| Manager / Joint Managers |
Citigroup/ Leerink Partners/ Wells Fargo Securities/ JMP Securities |
| Co Managers |
- |
| Expected to Trade |
10/2/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
